Last Price$86.0(2.7%)
Market Cap$34.9B
11.3%
Peers median - 3.1%
11.3%
Peers median - 15.3%
120.3%
Peers median - 29.9%
21.7%
Peers median - 11.2%
Competing with DXCM
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare DXCM Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
DexCom, Inc.DXCM
8.6x
11.3%
(1.4%)
14.3%
Median Peer Set
5.4x
4.1%
126.3%
11.8%
Abbott LaboratoriesABT
5.9x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
3.2x
3.4%
26.0%
11.5%
Boston Scientific CorporationBSX
9.9x
17.6%
16.7%
11.1%
Edwards Lifesciences CorporationEW
6.8x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
118.1%
(3.9%)
Insulet CorporationPODD
9.7x
30.0%
4,364.6%
12.2%
STERIS plcSTE
4.1x
3.6%
257.9%
7.4%
Stryker CorporationSYK
7.0x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
4.8x
6.5%
253.2%
13.8%
Compare DXCM Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does DexCom, Inc. (DXCM) revenue growth compare to peers and the industry?
DexCom, Inc. (DXCM) revenue growth is 11.3%, compared to the peers' median of 3.1%.
2. How does DexCom, Inc. (DXCM) Free Cash Flow (FCF) margin compare to peers and the industry?
DexCom, Inc. (DXCM) FCF margin is 11.3%, compared to the peers' median of 15.3%.
3. How does DexCom, Inc. (DXCM) Total Debt to Equity ratio compare to peers and the industry?
DexCom, Inc. (DXCM) Total Debt to Equity ratio is 120.3%, compared to the peers' median of 29.9%.
4. How does DexCom, Inc. (DXCM) ROIC (Return on Invested Capital) compare to peers and the industry?
DexCom, Inc. (DXCM) ROIC is 21.7%, compared to the peers' median of 11.2%.